Elevance Health, Inc. (ELV)
(Real Time Quote from BATS)
$547.36 USD
+1.40 (0.26%)
Updated Aug 26, 2024 01:02 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Elevance Health (ELV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$601.21 | $655.00 | $530.00 | 10.12% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Elevance Health comes to $601.21. The forecasts range from a low of $530.00 to a high of $655.00. The average price target represents an increase of 10.12% from the last closing price of $545.96.
Analyst Price Targets (19)
Broker Rating
Elevance Health currently has an average brokerage recommendation (ABR) of 1.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.27 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 80% and 10% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 10%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ELV.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 17 | 17 |
Buy | 2 | 2 | 2 | 2 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.27 | 1.27 | 1.27 | 1.17 | 1.16 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/22/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
7/19/2024 | Cowen & Co. | Ryan Langston | Strong Buy | Strong Buy |
7/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/17/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
6/18/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
4/19/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/19/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
4/19/2024 | UBS | Aj Rice | Not Available | Strong Buy |
4/18/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/1/2024 | Not Identified | Not Identified | Hold | Hold |
1/24/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.27 |
ABR (Last week) | 1.27 |
# of Recs in ABR | 20 |
Average Target Price | $601.21 |
LT Growth Rate | 12.30% |
Industry | Medical Services |
Industry Rank by ABR | 148 of 253 |
Current Quarter EPS Est: | 9.71 |